Imho Marsden should resist any temptation to suggest a price for SNG001 as it will surely be taken out of his hands once it reaches the market/s.
Synairgen has no marketing /sales capability, so it would depend on the JV partner to come upwith a suitable price depending on where it’s positioned.
Interestingly, imho Dr Fish has positioned her interferon beta 1b as a sort of preventative - once a family/group member has been diagnosed - but she’s needs Synairgen’s inhaled form, not subcutaneous.
SNG001 comes within the innate anti-viral ‘first responders’ so to price it against remdesivir seems wrong to me - although it could be a lifesaver for COPD patients suffering viral exacerbations.
On the face of it, to have only two institutions with >3% holdings doesn’t suggest that the SNG story has been particularly persuasive (yet?) and just adds to the volatility and fragility behind the sp - in spite of all the longtermer PIs.